Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

CORRECTION: Jefferies Initiates Coverage On CTI BioPharma with Buy Rating, Announces Price Target of $13 – Correct Analyst Firm Updated

CORRECTION:Jefferies analyst Kelly Shi initiates coverage on CTI BioPharma (NASDAQ:CTIC) with a Buy rating and announces Price Target of $13, correct Analyst Firm updated.
byBenzinga Newsdesk
September 1, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

CORRECTION:Jefferies analyst Kelly Shi initiates coverage on CTI BioPharma (NASDAQ:CTIC) with a Buy rating and announces Price Target of $13, correct Analyst Firm updated.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts